NCT06683755View on ClinicalTrials.gov

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

August 16, 2030

Study Completion Date

August 16, 2032

Conditions
Melanoma
Interventions
DRUG

Nivolumab

Given by IV

DRUG

Relatlimab

Given by IV

DRUG

Ipilimumab

Given by IV

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT06683755 - Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) | Biotech Hunter | Biotech Hunter